Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher D Lao

Showing results (81-90 of 86) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 86 results.
The New England Journal of Medicine|September 29, 2019
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced MelanomaJames Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
The New England Journal of Medicine|September 12, 2017
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced MelanomaJedd D Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
The New England Journal of Medicine|June 2, 2015
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaJames Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
The New England Journal of Medicine|September 16, 2024
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced MelanomaJedd D Wolchok, Vanna Chiarion-Sileni, Piotr Rutkowski, et al.
Nature Medicine|January 5, 2021
Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell eliminationJiali Yu, Michael D Green, Shasha Li, et al.
The New England Journal of Medicine|March 1, 2023
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced MelanomaSapna P Patel, Megan Othus, Yuanbin Chen, et al.
Pageof 9

Showing results (81-90 of 86) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 86 results.
The New England Journal of Medicine|September 29, 2019
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced MelanomaJames Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
The New England Journal of Medicine|September 12, 2017
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced MelanomaJedd D Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
The New England Journal of Medicine|June 2, 2015
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaJames Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
The New England Journal of Medicine|September 16, 2024
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced MelanomaJedd D Wolchok, Vanna Chiarion-Sileni, Piotr Rutkowski, et al.
Nature Medicine|January 5, 2021
Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell eliminationJiali Yu, Michael D Green, Shasha Li, et al.
The New England Journal of Medicine|March 1, 2023
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced MelanomaSapna P Patel, Megan Othus, Yuanbin Chen, et al.
Pageof 9